Longboard Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Longboard PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 0.7% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 79.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 5.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -29.6% betragen.

Wichtige Informationen

-0.7%

Wachstumsrate der Gewinne

6.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.5%
Wachstumsrate der Einnahmen	79.3%
Zukünftige Eigenkapitalrendite	-29.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:LBPH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5	-116	-98	-86	7
12/31/2025	N/A	-91	-91	-73	7
12/31/2024	2	-65	-57	-56	7
3/31/2024	N/A	-58	-53	-53	N/A
12/31/2023	N/A	-54	-51	-51	N/A
9/30/2023	N/A	-51	-50	-50	N/A
6/30/2023	N/A	-49	-46	-46	N/A
3/31/2023	N/A	-46	-41	-41	N/A
12/31/2022	N/A	-44	-38	-38	N/A
9/30/2022	N/A	-41	-34	-34	N/A
6/30/2022	N/A	-36	-30	-30	N/A
3/31/2022	N/A	-32	-27	-27	N/A
12/31/2021	N/A	-28	-25	-25	N/A
9/30/2021	N/A	-29	-21	-20	N/A
6/30/2021	N/A	-25	-15	-15	N/A
3/31/2021	N/A	-20	-11	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LBPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LBPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LBPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LBPHDie Einnahmen des Unternehmens (78.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: LBPHDie Einnahmen des Unternehmens (78.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: LBPH wird voraussichtlich in 3 Jahren unrentabel sein.

Longboard Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.2% to US$41.75

Price target increased by 43% to US$28.67

Price target decreased by 14% to US$17.00

Price target decreased to US$19.74

Price target decreased to US$22.80

Recent updates

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.